LLY

1,021.22

-2.93%↓

JNJ

243.76

+0.38%↑

ABBV

227

-2.16%↓

NVS

165.91

+0.18%↑

MRK

120.8

-0.53%↓

LLY

1,021.22

-2.93%↓

JNJ

243.76

+0.38%↑

ABBV

227

-2.16%↓

NVS

165.91

+0.18%↑

MRK

120.8

-0.53%↓

LLY

1,021.22

-2.93%↓

JNJ

243.76

+0.38%↑

ABBV

227

-2.16%↓

NVS

165.91

+0.18%↑

MRK

120.8

-0.53%↓

LLY

1,021.22

-2.93%↓

JNJ

243.76

+0.38%↑

ABBV

227

-2.16%↓

NVS

165.91

+0.18%↑

MRK

120.8

-0.53%↓

LLY

1,021.22

-2.93%↓

JNJ

243.76

+0.38%↑

ABBV

227

-2.16%↓

NVS

165.91

+0.18%↑

MRK

120.8

-0.53%↓

Search

Simulations Plus Inc

Avatud

SektorTervishoid

12.14 -0.25

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

11.72

Max

12.27

Põhinäitajad

By Trading Economics

Sissetulek

1.4M

676K

Müük

961K

18M

P/E

Sektori keskmine

48.528

121.746

Aktsiakasum

-0.034

Dividenditootlus

0.48

Kasumimarginaal

3.67

Töötajad

212

EBITDA

-3M

2.3M

Soovitused

By TipRanks

Soovitused

Osta

12 kuu keskmine prognoos

+54.6% upside

Dividendid

By Dow Jones

Dividenditootlus

Sektori keskmine

0.48%

2.26%

Järgmine tulemuste avaldamine

2. apr 2026

Turustatistika

By TradingEconomics

Turukapital

-120M

248M

Eelmine avamishind

12.39

Eelmine sulgemishind

12.14

Uudiste sentiment

By Acuity

30%

70%

85 / 351 Pingereas Healthcare

Simulations Plus Inc Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

17. veebr 2026, 23:44 UTC

Kuumad aktsiad

Stocks to Watch: La-Z-Boy, Palo Alto Networks, Caesars

17. veebr 2026, 23:20 UTC

Tulu

Palo Alto Networks Lifts FY26 Revenue Outlook as 2Q Profit Jumps -- Update

17. veebr 2026, 22:57 UTC

Tulu

Santos Fiscal Year Net Profit Falls 33%, Nears Start of Alaska Project

17. veebr 2026, 21:59 UTC

Tulu

Palo Alto Networks Lifts FY26 Revenue Outlook as 2Q Profit Jumps

17. veebr 2026, 23:54 UTC

Market Talk

Nikkei May Rise as Fears About AI Disruption Ease -- Market Talk

17. veebr 2026, 23:54 UTC

Market Talk

Global Equities Roundup: Market Talk

17. veebr 2026, 23:54 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

17. veebr 2026, 23:45 UTC

Market Talk

Suncorp's Outperformance of IAG Could Be Hard to Sustain -- Market Talk

17. veebr 2026, 23:19 UTC

Tulu

Palo Alto's Guidance Overshadows Strong Earnings. Its Stock Is Down. -- Barrons.com

17. veebr 2026, 23:15 UTC

Tulu

Palo Alto's Guidance Overshadows Strong Earnings. Its Stock Is Down. -- Barrons.com

17. veebr 2026, 22:58 UTC

Market Talk
Omandamised, ülevõtmised, äriostud

Netflix Would Operate Warner's Studios, HBO Largely the Same -- Market Talk

17. veebr 2026, 22:58 UTC

Omandamised, ülevõtmised, äriostud

BlueScope Steel: Board Committed to Optimizing Value For Shareholders

17. veebr 2026, 22:57 UTC

Omandamised, ülevõtmised, äriostud

BlueScope Steel to Consider Revised SGH, Steel Dynamics Takeover Bid

17. veebr 2026, 22:50 UTC

Omandamised, ülevõtmised, äriostud

Agnico-Eagle Mines Acquired 662,780 Common Shrs of Maple Gold Mines at C$2.45 Per Common Shr >AEM.T

17. veebr 2026, 22:44 UTC

Tulu

Palo Alto Reports Strong Earnings. Its Stock Is Down. -- Barrons.com

17. veebr 2026, 22:42 UTC

Tulu

Santos FY Net Profit Falls 33%, Nears Start of Alaska Project

17. veebr 2026, 22:36 UTC

Market Talk
Omandamised, ülevõtmised, äriostud

Netflix Sarandos: Paramount Causing Confusion Around Warner Deal -- Market Talk

17. veebr 2026, 22:36 UTC

Tulu

Santos Final Dividend 10.3 U.S. Cents/Security

17. veebr 2026, 22:36 UTC

Tulu

Santos FY Underlying Profit US$898 Million, Down 25%

17. veebr 2026, 22:35 UTC

Tulu

Santos FY Revenue US$4.94 Billion, Down 8%

17. veebr 2026, 22:35 UTC

Tulu

Correct: Santos FY Net Profit US$818 Million, Down 33%

17. veebr 2026, 22:35 UTC

Omandamised, ülevõtmised, äriostud

Berkshire Buys New York Times Stock; Sells Apple, Bank of America, Amazon In 4Q -- Barrons.com

17. veebr 2026, 22:34 UTC

Tulu

Santos FY Net Profit US$818 Billion, Down 33%

17. veebr 2026, 22:02 UTC

Omandamised, ülevõtmised, äriostud

Berkshire Pares Stakes in Apple and BofA, Adds New York Times Position -- Update

17. veebr 2026, 21:50 UTC

Omandamised, ülevõtmised, äriostud

Steel Dynamics: SGH Would Buy BlueScope, On-sell North American Operations to SDI, As Earlier Proposed

17. veebr 2026, 21:50 UTC

Market Talk
Omandamised, ülevõtmised, äriostud

Tech, Media & Telecom Roundup: Market Talk

17. veebr 2026, 21:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

17. veebr 2026, 21:49 UTC

Omandamised, ülevõtmised, äriostud

Steel Dynamics Says Revised Proposal Continues to Present Highly Strategic Opportunity For SDI Shareholders

17. veebr 2026, 21:48 UTC

Omandamised, ülevõtmised, äriostud

Steel Dynamics: BlueScope Offer a 56% Premium to 52-Week Volume Weighted Average Price

17. veebr 2026, 21:48 UTC

Omandamised, ülevõtmised, äriostud

Steel Dynamics: Consideration To Be Comprised Entirely of Cash

Võrdlus sarnastega

Hinnamuutus

Simulations Plus Inc Prognoos

Hinnasiht

By TipRanks

54.6% tõus

12 kuu keskmine prognoos

Keskmine 19 USD  54.6%

Kõrge 19 USD

Madal 19 USD

Põhineb 4 Wall Streeti analüütiku instrumendi Simulations Plus Inc 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Osta

4 ratings

2

Osta

2

Hoia

0

Müü

Sentiment

By Acuity

85 / 351 Pingereas Tervishoid

Uudiste sentiment

Languse märgid

Volatiilsus

Alla keskmise

Uudismaht (RCV)

Üle keskmise

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

$

Ettevõttest Simulations Plus Inc

Simulations Plus, Inc. develops drug discovery and development software for modeling and simulation, and prediction of molecular properties utilizing artificial intelligence and machine learning based technology worldwide. The company operates through Software and Services segments. It also offers GastroPlus, which simulates the absorption and drug interaction of compounds administered to humans and animals; and DDDPlus and MembranePlus simulation products. In addition, the company provides products based on mechanistic and mathematical models, such as DILIsym, NAFLDsym, ILDsym, IPFsym, RENAsym, MITOsym, and OBESITYsym products. Further, it offers Absorption, Distribution, Metabolism, Excretion, and Toxicity Predictor for chemistry-based computer program that takes molecular structures as inputs and predicts their properties; and MedChem Designer, as well as MonolixSuite products for modeling and simulation that allows for population analyses, rapid clinical trial data analyses, and regulatory submissions. Additionally, the company provides clinical-pharmacology-based consulting services, which includes population pharmacokinetic and pharmacodynamic modeling, exposure-response analyses, clinical trial simulations, data programming, and technical writing services in support of regulatory submissions; and early drug discovery services. Furthermore, it offers creative and insightful consulting services to support its quantitative systems pharmacology and other modeling systems. The company serves pharmaceutical, biotechnology, agrochemical, cosmetics, and food industry companies, as well as academic and regulatory agencies. Simulations Plus, Inc. was incorporated in 1996 and is headquartered in Lancaster, California.
help-icon Live chat